Skip to main content

BRIEF-Amgen receives positive CHMP opinion for ABP 501

* Amgen receives positive CHMP opinion for ABP 501 (biosimilar adalimumab) for the treatment of certain inflammatory diseases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.